Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.67 |
| ▸ | PPARG | P37231 | 5/20 | 0.67 |
| ▸ | F7 | P08709 | 4/20 | 0.67 |
| ▸ | F3 | P13726 | 4/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.67 |
| ▸ | PPARD | Q03181 | 4/20 | 0.67 |
| ▸ | PPARA | Q07869 | 4/20 | 0.67 |
| ▸ | FABP3 | P05413 | 3/20 | 0.67 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.67 |
| ▸ | FABP4 | P15090 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.67 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.67 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20074366 | 1.00 | ALDH1A1 (0.67) | ALDH1A1PPARGF7F3KDM4E | |
| SCHEMBL23950453 | 1.00 | ALDH1A1 (0.67) | ALDH1A1PPARGF7F3KDM4E | |
| SCHEMBL25834788 | 1.00 | ALDH1A1 (0.67) | ALDH1A1PPARGF7F3KDM4E | |
| SCHEMBL11892066 | 1.00 | ALDH1A1 (0.67) | ALDH1A1PPARGF7F3KDM4E | |
| SCHEMBL21147476 | 0.98 | PPARG (0.66) | ALDH1A1PPARGF7F3KDM4E | |
| SCHEMBL23950505 | 0.97 | ALDH1A1 (0.64) | ALDH1A1PPARGF7F3KDM4E | |
| SCHEMBL23950452 | 0.95 | TERT (0.63) | PPARGF7F3PPARDPPARA | |
| SCHEMBL23950440 | 0.95 | TERT (0.63) | PPARGF7F3PPARDPPARA | |
| SCHEMBL23950153 | 0.95 | TERT (0.63) | PPARGF7F3PPARDPPARA | |
| SCHEMBL21448814 | 0.95 | TERT (0.63) | PPARGF7F3PPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
| US-20210346507-A1 | GEMCITABINE PRODRUGS | CURE BIOPHARMA INC. | 2021-11-11 | — | — | US | disclosed |
| US-20210323992-A1 | GEMCITABINE PRODRUGS | CURE BIOPHARMA INC. | 2021-10-21 | — | — | US | disclosed |
| US-20200360334-A1 | New Uses of Lipophenolic Compounds | UNIVERSITE DE MONTPELLIER (FR) | 2020-11-19 | — | — | US | disclosed |
| US-10544154-B2 | Opioid receptor antagonist prodrugs | NIRSUM LABORATORIES, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-10450568-B2 | Oligonucleotide compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2019-10-22 | — | — | US | disclosed |
| US-20190307743-A1 | OPIOID RECEPTOR ANTAGONIST PRODRUGS | NIRSUM LABORATORIES, INC. | 2019-10-10 | — | — | US | disclosed |
| US-20190308988-A1 | OPIOID RECEPTOR ANTAGONIST PRODRUGS | NIRSUM LABORATORIES, INC. | 2019-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | ALDH1A1 1330/4885PPARG 271/4885F7 4629/4885 |
| US-20190307743-A1 | OPIOID RECEPTOR ANTAGONIST PRODRUGS | OPRM1, OPRK1, OPRL1 | ALDH1A1 725/4885PPARG 615/4885F7 4503/4885 |
| US-20210323992-A1 | GEMCITABINE PRODRUGS | TYMP, PIK3CA, DCK | ALDH1A1 2877/4885PPARG 869/4885F7 4597/4885 |
| US-10544154-B2 | Opioid receptor antagonist prodrugs | OPRM1, OPRK1, OPRL1 | ALDH1A1 725/4885PPARG 615/4885F7 4503/4885 |
| US-20190308988-A1 | OPIOID RECEPTOR ANTAGONIST PRODRUGS | OPRM1, OPRK1, OPRL1 | ALDH1A1 725/4885PPARG 615/4885F7 4503/4885 |
| US-20200360334-A1 | New Uses of Lipophenolic Compounds | MALT1, CCR1, LIPG | ALDH1A1 279/4885PPARG 989/4885F7 1794/4885 |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | ALDH1A1 2528/4885PPARG 498/4885F7 3177/4885 |
| US-10450568-B2 | Oligonucleotide compositions and methods thereof | RBM17, HNRNPA2B1, HNRNPA1 | ALDH1A1 3613/4885PPARG 2972/4885F7 4320/4885 |
| US-20210346507-A1 | GEMCITABINE PRODRUGS | TYMP, PIK3CA, DCK | ALDH1A1 2877/4885PPARG 869/4885F7 4597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.